{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:46:29Z","timestamp":1761129989410,"version":"build-2065373602"},"reference-count":27,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T00:00:00Z","timestamp":1644278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"This work was supported by Sinovac Biotech Co., Ltd..","award":["None"],"award-info":[{"award-number":["None"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background: The Sabin-strain-based inactivated poliovirus vaccine (sIPV) plays an important role in poliomyelitis eradication in developing countries. As part of the phase III clinical development program, this study aimed to evaluate the safety, immunogenicity and lot-to-lot consistency of the sIPV in 2-month-old infants. Method: We conducted a phase III, randomized, double-blind, positive-controlled trial in which 1300 healthy infants were randomly assigned to four groups in a 1:1:1:1 ratio to receive one of the three lots of the sIPV or the control IPV at 2, 3 and 4 months of age. Serum samples were collected before the first dose and 30 days after the third dose of vaccination to assess the immunogenicity. Solicited local and systemic reactions were recorded within 7 days and unsolicited adverse events within 30 days after each vaccination. Results: Of the 1300 randomized infants, 1190 infants completed the study and were included in the per-protocol population. The seroconversion rates in the three lots of the sIPV were 95.67%, 97.03% and 95.59%, respectively, for type 1; 94.33%, 93.73% and 92.88%, respectively, for type 2; and 98.67%, 99.67% and 99.32%, respectively, for type 3. The ratios of GMTs for poliovirus types 1, 2 and 3 of each pair of lots were all between 0.67 and 1.50, therefore meeting the predefined immunological equivalence criteria. For the seroconversion rate of poliovirus types 1, 2 and 3, the pooled sIPV group was non-inferior to the IPV group. The incidence of solicited and unsolicited adverse reactions (ARs) was similar in the pooled sIPV lots and the IPV group, and most of them were mild to moderate in severity. Non-vaccine-related serious adverse events (SAEs) were reported. Conclusions: Three consecutive lots of sIPV demonstrated robust and consistent immunogenicity. The safety and tolerability of the sIPV was acceptable and similar to that of the IPV.<\/jats:p>","DOI":"10.3390\/vaccines10020254","type":"journal-article","created":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T23:42:20Z","timestamp":1644363740000},"page":"254","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Safety, Immunogenicity and Lot-to-Lot Consistency of Sabin-Strain Inactivated Poliovirus Vaccine in 2-Month-Old Infants: A Double-Blind, Randomized Phase III Trial"],"prefix":"10.3390","volume":"10","author":[{"given":"Yan","family":"Zheng","sequence":"first","affiliation":[{"name":"Vaccine Clinical Research Center, Yunnan Provincial Center for Disease Control and Prevention, Kunming 650034, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhifang","family":"Ying","sequence":"additional","affiliation":[{"name":"Respiratory Virus Vaccine Department, Biological Product Institute, National Institutes for Food and Drug Control, Beijing 100050, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanxiang","family":"Zou","sequence":"additional","affiliation":[{"name":"Vaccine Clinical Research Center, Yunnan Provincial Center for Disease Control and Prevention, Kunming 650034, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taotao","family":"Zhu","sequence":"additional","affiliation":[{"name":"Clinical Research Department, Sinovac Biotech Co., Ltd., Beijing 100089, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dinggu","family":"Qian","sequence":"additional","affiliation":[{"name":"Vaccine Clinical Research Project Office, Qiubei County Center for Disease Control and Prevention, Wenshan Zhuang and Miao Autonomous Prefecture 663299, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7804-3786","authenticated-orcid":false,"given":"Weixiao","family":"Han","sequence":"additional","affiliation":[{"name":"Clinical Research Department, Sinovac Biotech Co., Ltd., Beijing 100089, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya","family":"Jiang","sequence":"additional","affiliation":[{"name":"Vaccine Clinical Research Project Office, Mile County Center for Disease Control and Prevention, Honghe Hani and Yi Autonomous Prefecture 652399, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiwei","family":"Jiang","sequence":"additional","affiliation":[{"name":"Statistics Department, Beijing Key Tech Statistical Consulting Co., Ltd., Beijing 100025, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingyan","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Acute Infectious Disease Control and Prevention, Yanshan County Center for Disease Control and Prevention, Wenshan Zhuang and Miao Autonomous Prefecture 663299, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianfeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Clinical Research Department, Sinovac Biotech Co., Ltd., Beijing 100089, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Lei","sequence":"additional","affiliation":[{"name":"Immunization Program Division, Gejiu County Center for Disease Control and Prevention, Honghe Hani and Yi Autonomous Prefecture 661099, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Xu","sequence":"additional","affiliation":[{"name":"Quality Assurance Department, Sinovac Biotech Co., Ltd., Beijing 100089, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deyu","family":"Jiang","sequence":"additional","affiliation":[{"name":"R&D Department, Sinovac Life Sciences Co., Ltd., Beijing 102629, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changgui","family":"Li","sequence":"additional","affiliation":[{"name":"Respiratory Virus Vaccine Department, Biological Product Institute, National Institutes for Food and Drug Control, Beijing 100050, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqiang","family":"Liu","sequence":"additional","affiliation":[{"name":"Vaccine Clinical Research Center, Yunnan Provincial Center for Disease Control and Prevention, Kunming 650034, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,8]]},"reference":[{"key":"ref_1","first-page":"595","article-title":"Medicine and the media: Polio still paralyses (Albert Sabin, Jonas Salk)","volume":"18","author":"Dixon","year":"1977","journal-title":"Br. J. Hosp. Med."},{"key":"ref_2","unstructured":"World Health Organization (2021, November 17). Does Polio Still Exist? Is It Curable?. Available online: http:\/\/www.who.int\/features\/qa\/07\/en\/."},{"key":"ref_3","unstructured":"Centers for Disease Control and Prevention (2022, January 03). What We Do, Available online: https:\/\/www.cdc.gov\/polio\/what-we-do\/."},{"key":"ref_4","unstructured":"Centers for Disease Control and Prevention (2001). Certification of poliomyelitis eradication\u2014Western Pacific Region, October 2000. MMWR Morb. Mortal. Wkly Rep., 50, 1\u20133."},{"key":"ref_5","unstructured":"International Graduate Programs for Educators (2021, November 17). Polio This Week. Available online: https:\/\/polioeradication.org\/polio-today\/polio-now\/this-week\/."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0140-6736(17)32442-X","article-title":"The polio endgame: Securing a world free of all polioviruses","volume":"391","author":"Zaffran","year":"2018","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"S380","DOI":"10.1093\/infdis\/jiu184","article-title":"Vaccine-associated paralytic poliomyelitis: A review of the epidemiology and estimation of the global burden","volume":"210","author":"Platt","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"S283","DOI":"10.1093\/infdis\/jiu295","article-title":"M Vaccine-derived polioviruses","volume":"210","author":"Burns","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_9","unstructured":"World Health Organization (2021, November 17). Polio Eradication and Endgame Strategic Plan: 2013\u20132018. Available online: http:\/\/polioeradication.org\/whowe-are\/strategic-plan-2013-2018\/."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"934","DOI":"10.15585\/mmwr.mm6535a3","article-title":"Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine\u2014Worldwide, 2016","volume":"65","author":"Hampton","year":"2016","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"ref_11","unstructured":"Global Polio Eradication Initiative (2021, January 18). The Polio Endgame Strategy 2019\u20132023. Available online: http:\/\/polioeradication.org\/wp-content\/uploads\/2019\/06\/english-polio-endgame-strategy.pdf."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S459","DOI":"10.1093\/infdis\/jiu128","article-title":"B Affordable inactivated poliovirus vaccine: Strategies and progress","volume":"210","author":"Okayasu","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/j.vaccine.2014.11.015","article-title":"Development and introduction of inactivated poliovirus vaccines derived from Sabin strains in Japan","volume":"34","author":"Shimizu","year":"2016","journal-title":"Vaccine"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.biologicals.2016.08.005","article-title":"W Development of inactivated poliovirus vaccine from Sabin strains: A progress report","volume":"44","author":"Okayasu","year":"2016","journal-title":"Biologicals"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"7188","DOI":"10.1016\/j.vaccine.2011.05.079","article-title":"A Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV","volume":"29","author":"Bakker","year":"2011","journal-title":"Vaccine"},{"key":"ref_16","first-page":"1032","article-title":"B [The role of Sabin inactivated poliovirus vaccine in the final phase of global polio eradication]","volume":"50","author":"Dong","year":"2016","journal-title":"Zhonghua Yu Fang Yi Xue Za Zhi"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/14760584.2021.1919091","article-title":"Cross-neutralization Capacity of Immune Serum from Different Dosage of Sabin Inactivated Poliovirus Vaccine Immunization against Multiple Individual Polioviruses","volume":"20","author":"Chu","year":"2021","journal-title":"Expert Rev. Vaccines"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"6782","DOI":"10.1016\/j.vaccine.2018.09.023","article-title":"Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: A phase II, randomized, dose-finding trial","volume":"36","author":"Chu","year":"2018","journal-title":"Vaccine"},{"key":"ref_19","first-page":"1","article-title":"Immunogenicity and safety of an inactivated enterovirus 71 vaccine co-administered with measles-mumps-rubella vaccine and live-attenuated Japanese encephalitis vaccine: A phase 4, single-center, randomized controlled trial","volume":"12","author":"Liu","year":"2021","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_20","unstructured":"Administration, C.N.M.P. (2021, November 11). Guidelines for Grading Standards of Adverse Events in Clinical Trials of Preventive Vaccines, Available online: https:\/\/www.nmpa.gov.cn\/xxgk\/ggtg\/qtggtg\/20191231111901460.html."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/infdis\/jiy736","article-title":"Immunogenicity and Safety of a Sabin Strain-Based Inactivated Polio Vaccine: A Phase 3 Clinical Trial","volume":"220","author":"Hu","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1093\/infdis\/jiw433","article-title":"Phase 3 Trial of a Sabin Strain-Based Inactivated Poliovirus Vaccine","volume":"214","author":"Liao","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/1096-9071(200104)63:4<305::AID-JMV1006>3.0.CO;2-U","article-title":"Age- and dose-interval-dependent antibody responses to inactivated poliovirus vaccine","volume":"63","author":"Sormunen","year":"2001","journal-title":"J. Med. Virol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1080\/21645515.2019.1572410","article-title":"Effect of maternal antibody on the infant immune response to inactivated poliovirus vaccines made from Sabin strains","volume":"15","author":"Tang","year":"2019","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1086\/508427","article-title":"A Serologic response to inactivated poliovirus vaccine: A randomized clinical trial comparing 2 vaccination schedules in Puerto Rico","volume":"195","author":"Dayan","year":"2007","journal-title":"J. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1016\/j.vaccine.2014.07.029","article-title":"A Safety and immunogenicity of a primary series of Sabin-IPV with and without aluminum hydroxide in infants","volume":"32","author":"Verdijk","year":"2014","journal-title":"Vaccine"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/infdis\/jir723","article-title":"Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: A phase II, randomized, positive-controlled trial","volume":"205","author":"Liao","year":"2012","journal-title":"J. Infect. Dis."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/2\/254\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:15:53Z","timestamp":1760134553000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/2\/254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,8]]},"references-count":27,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["vaccines10020254"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10020254","relation":{},"ISSN":["2076-393X"],"issn-type":[{"type":"electronic","value":"2076-393X"}],"subject":[],"published":{"date-parts":[[2022,2,8]]}}}